Thomas A. Moore
Chief Executive Officer and Chairman of the Board of Directors
Effective December 15, 2006, Thomas Moore was named our Chairman and Chief Executive Officer. He is currently also Director at Alteon, Inc., a publicly traded developer of pharmaceuticals for the treatment of diabetes and age-related diseases, El Dorado Inc., a targeted marketer to unassimilated Hispanics, Medmeme, which measures medical education effectiveness, MD Offices, an electronic medical records provider, and Opt-e-scrip, Inc., which markets a clinical system to compare multiple drugs in the same patient. He also serves as Chairman of the Board of Directors of Mayan Pigments, Inc., which has developed and patented Mayan pigment technology. Previously, from June 2002 to June 2004 Mr. Moore was President and Chief Executive Officer of Biopure Corporation, a developer of oxygen therapeutics that are intravenously administered to deliver oxygen to the body's tissues. From 1996 to November 2000 he was President and Chief Executive Officer of Nelson Communications. Previously, Mr. Moore had a 23-year career with the Procter & Gamble Company in multiple managerial positions, including President of Health Care Products where he was responsible for prescription and over-the-counter medications worldwide, and group vice president of the Procter & Gamble Company.
John Rothman, Ph.D.
Vice President of Clinical Development
Dr. Rothman joined Advaxis Inc. in March of 2005 as Vice President of Clinical Development. Prior to that between 2001 and 2003 he and a colleague purchased a 180 bed hospital from the University of Ohio system, sold it to an African Chief, and moved the facility to Ibaden Nigeria. From 2002 to 2005 Dr. Rothman was Vice President and Chief Technology Officer of Princeton Technology Partners. Prior to that he was involved in the development of the first interferon at Schering Inc., was director of a variety of clinical development sections at Hoffman LaRoche, and the Senior Director of Clinical Data Management at Roche. While at Roche his work in Kaposis’ Sarcoma became the clinical basis for the first filed BLA which involved the treatment of AIDS patients with interferon.
Vafa Shahabi, Ph.D.
Director of Research and Development
Dr. Shahabi joined the Company in March 2005 and brings 12 years of experience in vaccine research to Advaxis. Previously, she worked as a Sr. Research Scientist at Wyeth, developing vaccines against viral infections such as HIV and HPV-associated tumors. Dr. Shahabi has also worked at Apollon in Malvern, PA, where her research focused on developing a DNA vaccine against HPV; at the Medical School of the University of Gothenburg-Sweden where she served as a Research Scientist and developed vaccines against Cholera and ETEC-associated diseases; as a postdoctoral fellow at School of Medicine-University of Pennsylvania, where she developed Listeria monocytogenes-based vaccines. Dr. Shahabi has several publications in peer-reviewed scientific journals. Dr. Shahabi holds a BS in Pharmacy from University of Madrid-Spain and a Ph.D. in Pharmacology from Temple University- School of Medicine.
